Amarin Corp Plc (AMRN)

[KashSmooth]

Anyone have any thoughts on the 40% reduction in channel inventory in Q1 2022?

From ST Message Board by GreenTurtleValueInvestor:

2nd Message (in reply):
In some cases, it’s a sign of upcoming M&A. The acquirer will mandate the targeted company to lower their channel inventory significantly because they want the clean business from new start (i.e. no big return from wholesalers at the start of new operation. Anyway, it may be just my wishful thinking. ??

1st Message
Trying to digest 10-Q Form and reading between the lines if the Q1 collapse is a result of inept management or a kind of preparation for something big in Q2...

- US Revenue dropped by -34% from $141 to $94 mil
- Half of the impact is from Generics. Balance of the impact is the "Selling initiatives" (which I can't understand clearly).
- Icosapent Ethyl market (per Symphony Health), grew by +11%
- Vascepa prescription (per Symphony Health) dropped by -12%
- Vascepa Market Share dropped from 91% to 72% (this is terrible because generics took 28% of shares.)
- Wholesalers reduces their channel inventory by -40% (to the low-end of the range, but why? )

Normally, the company reduces wholesaler's inventory (aka. channel inventory) this much in preparation of something big.. let's see if it's my daydream or not...